Document:

srne-ex102_166.htm

Exhibit 10.2

 

*** Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. ***

OMNIBUS AMENDMENT NO. 2 TO INDENTURE AND LETTER OF CREDIT

This OMNIBUS AMENDMENT NO. 2 TO INDENTURE AND LETTER OF CREDIT, dated as of March 30, 2020 (this “Amendment”), is among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Issuer”), SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Parent Guarantor”), U.S. BANK NATIONAL ASSOCIATION, as trustee (in such capacity, together with its successors and assigns in such capacity, the “Trustee”) and collateral agent (in such capacity, together with its successors and assigns in such capacity, the “Collateral Agent”) under the Indenture (as defined below), and the beneficial owners of the Securities and the Holders listed on the signature pages hereof (collectively, the “Holders”).

RECITALS

WHEREAS, the Issuer, the Parent Guarantor, the Trustee and the Collateral Agent are parties to that certain Indenture, dated as of September 7, 2018 (as modified and supplemented and in effect from time to time, the “Indenture”), pursuant to which the Issuer issued Senior Secured Notes due 2026 in the aggregate principal amount of $224,000,000;

WHEREAS, pursuant to the Indenture, the Parent Guarantor issued to the Issuer that certain Irrevocable Standby Letter of Credit in the maximum aggregate amount of $35,000,000, with a date of issuance of September 7, 2018 (the “Letter of Credit”); and

WHEREAS, the Issuer has requested that the Holders, the Trustee and the Collateral Agent agree to amend the Indenture and the Letter of Credit in certain respects, in each case as set forth in this Amendment.

NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:

Section 1.Definitions.  Except as otherwise defined in this Amendment, terms defined in the Indenture are used herein as defined therein.

Section 2.Amendments.  Each of the parties hereto agrees that, effective on the Effective Date (as defined in Section 5):

(a)The defined term “Additional Amount” is hereby added in alphabetical order to Section 1.01 of the Indenture as follows:

“Additional Amount” means, for each full calendar month, commencing June 2020 and ending March 2021, in which the Issuer does not have [...***...], an amount equal to $100,000 per month up to $1,000,000 in the aggregate; provided, however, that the Trustee and each Holder shall have received written notice from the Issuer promptly following the Issuer’s entry into such [...***...]; provided, further, that, for the avoidance of doubt and notwithstanding the foregoing, the ability of the Issuer to Incur such  [...***...] and the 

 

 

[...***...] shall have been separately consented to and approved in accordance with the terms of Section 9.02 of the Indenture; provided, further, that the Holders shall not unreasonably withhold or delay consent to such [...***...] on terms substantially similar to those in [...***...]; provided, further, that such [...***...] does not require [...***...]. 

(b)The definition “Minimum Cash Provision” in Section 1.01 of the Indenture is hereby deleted in its entirety and replaced with the following:

“Minimum Cash Provision” means the provision set forth in the Letter of Credit specifying the amount that the Issuer is required to hold in Cash Equivalents in the Collateral Account and other bank accounts, as of the end of any calendar month, in order not to trigger a drawing condition under the Letter of Credit, which amount is at least $29,000,000 for the month ending March 31, 2020 through and including the month ending March 31, 2021, and for each month ending thereafter, at least $35,000,000 plus the Additional Amount, if any.

(c)The reference to “$25,000,000” in the second sentence of clause (c) of Section 4.25 of the Indenture and in the second sentence of clause (d) of Section 4.25 of the Indenture is hereby deleted and replaced in both sentences with the phrase “$25,000,000 plus the Additional Amount (if any)”.

(d)The following new clause (e) is added to Section 4.25:

(e)The Issuer shall deposit, or cause to be deposited, the Additional Amount, if any, into the Collateral Account on or before April 1, 2021.

(f)Section 4.02(l) of the Indenture is hereby deleted in its entirety and replaced with the following:

(1)Monthly Net Sales and Financial Reports.  The Issuer shall deliver to the Trustee and each Holder no later than (i) ten Business Days after the end of each calendar month, (A) an Officers’ Certificate setting forth Net Sales of the Product for such calendar month, the number of units of the Product sold during such calendar month and the calculation showing the reconciliation of gross worldwide sales of the Product for such calendar month to Net Sales of the Product for such calendar month and (B) a screen shot of the cash balance held in each account of the Issuer as of the end of such month, and (ii) the end of each calendar month, an unaudited, internal consolidated balance sheet of the Issuer and its Subsidiaries, if any, as of the end of the immediately preceding calendar month, and the related consolidated statement of income of the Issuer and its Subsidiaries, if any, in each case, prepared and presented on a basis generally consistent with other similar reporting required hereunder for unaudited financials.

(g)Clause (B1) of Exhibit 1 of the Letter of Credit is hereby deleted in its entirety and replaced with the following two paragraphs, each of which shall be an independent drawing condition for the Letter of Credit:

[(B1a) Scilex has failed to hold, as of the end of the most recently ended calendar month, commencing with the month ending March 31, 2020 through and including the month ending March 31, 2021, at least US$29,000,000 in (i) Cash Equivalents in the Collateral Account and (ii) aggregate unrestricted Cash Equivalents in bank accounts other than the Collateral Account.]

2

 

or

[(B1b) Scilex has failed to hold, as of the end of the most recently ended calendar month, commencing with the month ending April 30, 2021, (x) at least US$35,000,000 plus an additional amount (collectively, the “Additional Amount”) equal to US$100,000 for each full calendar month, commencing June 2020 and ending March 2021, in which Scilex does not have [...***...] in (i) Cash Equivalents in the Collateral Account (including the Additional Amount, if any) and (ii) aggregate unrestricted Cash Equivalents in bank accounts other than the Collateral Account and (y) at least US$25,000,000 plus the Additional Amount, if any, in Cash Equivalents in the Collateral Account.]

Section 3.Representations and Warranties of the Issuer and the Parent Guarantor.  Each of the Issuer and the Parent Guarantor represents and warrants as follows:

(a)as of the date hereof, the representations and warranties contained in the Indenture, the Securities, the Collateral Agreement, the Purchase Agreements or in any Security Document (each as amended hereby) are true and correct in all material respects as though made on and as of such date (except where such representations and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct in all material respects as of such earlier date); provided that any representation or warranty that is qualified as to “materiality”, “Material Adverse Effect” or similar language shall be true and correct in all respects on such respective dates;

(b)as of the date hereof, no event has occurred and is continuing that constitutes a “Default” or “Event of Default” under the Indenture, the Securities or any Security Document, and the execution, delivery and performance of this Amendment will not cause or constitute any such Default or Event of Default under the Indenture, the Securities or any Security Document, as amended hereby;

(c)as of the date hereof, the Issuer has accounts receivable of at least $6,000,000 (net of any amounts which have been disputed in writing) that are not more than 45 days past the due date therefor and that the Issuer reasonably believes are imminently collectible;

(d)an amount not less than $6,000,000 shall be used solely for the Commercialization of ZTlidoTM (lidocaine topical system 1.8%), whether marketed under this name or any other name, regardless of the purpose for which such product is marketed or sold (for the avoidance of doubt, excluding ZTlidoTM (lidocaine topical system 5.4%), any similar product with a concentration of not less than 5% and any other future iterations, improvements or modifications of ZTlidoTM (lidocaine topical system 1.8%) made, developed or licensed (or sub-licensed) by the Issuer or any of its Affiliates or licensees (or sub-licensees)); and

(e)each of the Issuer and the Parent Guarantor has duly authorized, executed and delivered this Amendment, and this Amendment constitutes the legal, valid and binding obligation of the Issuer and the Parent Guarantor enforceable against such person in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, moratorium, reorganization and other similar laws relating to or affecting creditors’ rights generally and general principles of equity (whether considered in a proceeding in equity or law).

3

 

Section 4.Representations and Warranties, and Covenant, of the Holders.

(a)Representations and Warranties.  Each Holder hereby represents and warrants, with respect to itself, to each of the Trustee and the Collateral Agent that as of the date hereof (i) such Holder owns or beneficially owns, respectively, the principal amount of the Securities set forth opposite such Holder’s name under the column heading “Principal Amount of Securities” in Schedule 1 attached hereto and, if such Securities are beneficially owned through the book-entry system of The Depository Trust Company, then such Securities are held through The Depository Trust Company participant set forth opposite such Holder’s name under the column heading “Depository Trust Company Participant Name and Number” in Schedule 1 attached hereto (and if nothing is set forth opposite such Holder’s name under the column heading “Depository Trust Company Participant Name and Number” in Schedule 1 attached hereto then such Holder does not hold such Securities through the book-entry system of The Depository Trust Company), (ii) the CUSIP Number of such Securities that are beneficially owned by such Holder are set forth opposite such Holder’s name under the column heading “CUSIP No.” in Schedule 1 attached hereto, (iii) such Holder is not the Issuer, the Parent Guarantor or a Subsidiary of the Issuer or the Parent Guarantor, (iv) such Holder has the full power and authority to provide this Amendment with respect to such Securities that are owned or beneficially owned by such Holder and (v) this Amendment has been duly executed and delivered by such Holder, and this Amendment constitutes a legal, valid and binding obligation of such Holder enforceable against such Holder in accordance with its terms.

(b)Covenant.  Each Holder (on a several and not joint basis) agrees to indemnify and hold harmless the Trustee and the Collateral Agent from and against any and all damages, losses, costs and expenses (including, without limitation, legal fees and expenses) arising or resulting from reliance upon the representations and warranties by such Holder set forth in this SECTION 4.

Section 5.Effectiveness.  This Amendment shall become effective as of the date that the Trustee shall have received (i) counterparts of this Amendment executed by the Trustee, the Issuer, the Parent Guarantor and the Collateral Agent, and (ii) counterparts of this Amendment executed by all the Holders of the then outstanding Securities (such date, the “Effective Date”).

Section 6.Effect on the Indenture, Letter of Credit, Securities, Purchase Agreement and Security Documents.

(a)On and after the Effective Date each reference in the Indenture to “this Indenture,” “hereunder,” “hereof,” “herein” or words of like import, and each reference in the Letter of Credit, the Securities, the Purchase Agreement or any Security Documents to the Indenture, shall mean and be a reference to the Indenture as amended hereby.

(b)On and after the Effective Date each reference in the Letter of Credit to “this Letter of Credit,” “hereunder,” “hereof,” “herein” or words of like import, and each reference in the Indenture, the Securities, the Purchase Agreement or any Security Documents to the Letter of Credit, shall mean and be a reference to the Letter of Credit as amended hereby.

4

 

(c)Except as specifically amended above, the Indenture, the Letter of Credit, the Securities, the Purchase Agreement and the Security Documents shall remain in full force and effect and are hereby ratified and confirmed.

(d)Except as set forth in this Amendment, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Trustee, the Collateral Agent or any of the Holders under the Indenture, the Letter of Credit, the Securities, the Purchase Agreement or any of the Security Documents, nor constitute a waiver of any provision thereof.

(e)None of the Trustee, the Collateral Agent or any Holder is under any obligation to enter into or consent to this Amendment.  The entering into of this Amendment by the Trustee and the Collateral Agent and any consent to this Amendment by any Holder shall not be deemed to limit or hinder any rights of any such party under the Indenture, the Letter of Credit, the Securities, the Purchase Agreement or any Security Document, nor shall it be deemed to create or infer a course of dealing between any such party, on the one hand, and the Parent Guarantor or the Issuer, on the other hand, with regard to any provision thereof.

Section 7.Authorization of Trustee and Collateral Agent.  Each of the Trustee and the Collateral Agent is hereby authorized, empowered and directed by the undersigned to execute and deliver this Amendment and to execute any documents or take any actions reasonably necessary in order to effectuate this Amendment.

Section 8.General Authorization.  Any and all actions heretofore or hereafter taken by the Trustee, the Collateral Agent, the Issuer, the Parent Guarantor and/or any officer, director, member, manager, partner, employee, contractor, Affiliate, attorney, representative and/or agent of any of the foregoing consistent with the intent and purpose of the matters approved or consented to in this Amendment are hereby ratified, confirmed, approved and consented to in all respects.

Section 9.Execution in Counterparts; Facsimile Signatures.  The parties may sign any number of copies of this Amendment.  Each signed copy shall be an original, but all of them together represent the same agreement.  The exchange of copies of this Amendment and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Amendment as to the parties hereto and may be used in lieu of the original Amendment for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

Section 10.Governing Law.  This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York without regard to principles of conflicts of law.

Section 11.Severability.  In case any provision in this Amendment shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

5

 

Section 12.Headings.  The headings of the Sections of this Amendment have been inserted for convenience of reference only, are not intended to be considered a part hereof and shall not modify or restrict any of the terms or provisions hereof.

Section 13.Binding Effect and Notice.  After the Effective Date, this Amendment shall bind each Holder (and such Holder’s successors and assigns) and every subsequent owner or beneficial owner of the Securities described on Schedule 1 attached hereto (or portion thereof that evidences the same debt as such Securities).  Any and all notice required to take any action in adopting this Amendment is hereby waived.  Each Holder acknowledges that this Amendment constitutes the required notice of this Amendment pursuant to Section 9.02(b) of the Indenture.  Each Holder and beneficial owner signatory hereto further agrees that such Holder’s or beneficial owner’s consent to this Amendment, and waiver of the applicable Indenture provisions expressly provided herein, shall not be revoked by such Holder or beneficial owner, and may not be revoked by any successors or assigns of such Holder or beneficial owner, prior to the Effective Date, notwithstanding the provisions of Section 9.03 of the Indenture.

[Signature Pages Follow]

 

6

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

	
ISSUER:

	
 
	
 
	
 

	
SCILEX PHARMACEUTICALS INC.

	
 
	
 
	
 

	
By:
	
 
	
/s/ Jaisim Shah

	
Name:
	
 
	
Jaisim Shah

	
Title:
	
 
	
Chief Executive Officer

 

	
PARENT GUARANTOR:

	
 
	
 
	
 

	
SORRENTO THERAPEUTICS, INC.

	
 
	
 
	
 

	
By:
	
 
	
/s/ Henry Ji, Ph.D.

	
Name:
	
 
	
Henry Ji, Ph.D.

	
Title:
	
 
	
President, Chief Executive Officer and

Chairman of the Board

[Signature Page to Omnibus Amendment No. 2 to Indenture and Letter of Credit]

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

	
TRUSTEE:

	
 
	
 
	
 

	
U.S. BANK NATIONAL ASSOCIATION, 

as Trustee

	
 
	
 
	
 

	
By:
	
 
	
/s/ Alison D.B. Nadeau

	
Name:
	
 
	
Alison D.B. Nadeau

	
Title:
	
 
	
Vice President

 

	
COLLATERAL AGENT:

	
 
	
 
	
 

	
U.S. BANK NATIONAL ASSOCIATION, 

as Collateral Agent

	
 
	
 
	
 

	
By:
	
 
	
/s/ Alison D.B. Nadeau

	
Name:
	
 
	
Alison D.B. Nadeau

	
Title:
	
 
	
Vice President

 

 

 

[Signature Page to Omnibus Amendment No. 2 to Indenture and Letter of Credit]

 

SCHEDULE 1

	
Name
	
Depository Trust Company Participant
Name and Number
	
Principal Amount of Securities
	
CUSIP No.

 

LEGAL_US_W # 102429897.2srne-ex103_167.htm

Exhibit 10.3

March 31, 2020

Nanjing Hongjing Enterprise Management Consulting Co., Ltd.

Executive Director

Room 2606, International Trade Center, No.18 East Zhongshan Road, Nanjing, China, 210005

Dear Mr Men:

Thank you for expressing an interest in the acquisition of Levena (Suzhou) Biopharma Co., Ltd., a Chinese corporation, located at B8-301, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, China (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (“Sorrento”), or such other entity that contains all operational assets of the Levena business (the “Acquisition”).

When executed by Nanjing Hongjing Enterprise Management Consulting Co., Ltd. (the “Purchaser”), in the manner hereinafter provided, this letter will be a binding letter of intent (this “Letter Agreement”) for the Acquisition.  The contents of this Letter Agreement are strictly confidential and this Letter Agreement is being provided by Sorrento to Purchaser pursuant to that certain non-disclosure agreement, dated March 28, 2020, by and between Sorrento and Purchaser (the “NDA”).  Accordingly, this letter should not be shared or discussed with any parties outside of Sorrento and Purchaser, other than their respective advisors who have a need to know such information in order to fulfill their professional responsibilities and who are subject to confidentiality obligations at least as restrictive as those contained in the NDA.

	
1.
	
Terms; Definitive Documents.  The key terms of the Acquisition are set forth on Exhibit A hereto, though the terms set forth therein do not contain all the terms and conditions that will govern the Acquisition, which additional terms shall be subject to mutual agreement.  Promptly following the effectiveness of this Letter Agreement, each party will negotiate in good faith to agree upon: (a) a definitive written agreement to be executed by the parties setting forth the terms of the Acquisition (the “Definitive Agreement”) and incorporating the terms set forth in this Letter Agreement (including Exhibit A, which is hereby incorporated by reference) and such other customary representations, warranties, covenants and terms as are necessary and appropriate for transactions similar to the Acquisition and as are mutually agreed.

	
2.
	
Due Diligence; Access; Necessary Approvals and Other Conditions.  Execution of a definitive agreement will be subject to customary due diligence by Purchaser and its attorneys, accountants and other advisors.  Sorrento will give Purchaser and its attorneys, accountants and other advisors reasonable access to any and all advisors, facilities, copies of all books and records and other information through closing (other than privileged information and certain board minutes or other materials relating to Sorrento’s consideration of strategic alternatives) with respect to Levena.  Additionally, Sorrento will give Purchaser and its attorneys, accountants and advisors reasonable access to Levena’s senior management on a mutually agreed to schedule.  Due diligence shall be conducted in a manner intended to obtain sufficient information with minimal disturbance to the employees of Sorrento and Levena.  Each party’s obligation to enter into the Definitive Agreement (on terms that are reasonably agreeable to Purchaser and Sorrento consistent with the contents of this letter) is subject to any necessary corporate approvals of each party.

	
3.
	
Conduct of Business.  From the date hereof until June 30, 2020, Sorrento agrees to use commercially reasonable efforts to continue to preserve and operate the Levena business in the ordinary course, consistent with past practice, including commercially reasonable efforts to preserve Levena’s existing business organization, assets, and relations with its employees, suppliers, customers and others with whom it has a business relationship.

 

 

	
4.
	
No Publicity; Confidentiality.  The parties will not, and each of them will cause their respective affiliates and representatives to not, make any public statement or issue any press release or announcement or otherwise make any disclosure to any third party (other than such representatives of a party as need to know such information for purposes of negotiating the Acquisition) concerning the terms or existence of this Letter Agreement (or the Definitive Agreement), the Acquisition or the discussions relating thereto except as may be required by applicable law or stock exchange rules, as reasonably necessary to satisfy lender requirements under any debt documents to which Sorrento is subject, or as otherwise may be mutually agreed in writing by the parties: provided, however, that any party so required to disclose any such information must use commercially reasonable efforts to consult with the other party prior to making any such disclosure.

	
5.
	
Effect of this Letter.  The terms set forth in this Letter Agreement are intended to be binding on the parties.

	
6.
	
Termination.  This Letter Agreement may be terminated at any time prior to entry into the Definitive Agreement:

(a)by mutual written consent of the parties;

(b)by either party if the Definitive Agreement shall not have been executed on or before June 30, 2020; provided that no party shall have the right to terminate pursuant to this Paragraph 6(b) if such party is responsible for the failure to enter into the Definitive Agreement by such date (for avoidance of doubt, in the event either party fails to approve or consent to a provision or condition precedent which by the terms of this Letter Agreement requires such party’s discretion, such failure shall not be deemed the responsibility of the other party);

(c)by either party in the event that any governmental authority shall have issued an order, decree or ruling or taken any other action restraining, enjoining or otherwise prohibiting the Acquisition; or

(d)by either party in the event that the parties are unable to agree on the form and scope of customary representations and warranties in the Definitive Agreement or the content of the related disclosure schedules.

	
7.
	
Fees and Expenses.  Each party will pay its own fees, costs and expenses related to this Letter Agreement, the negotiation of the Definitive Agreement and any documentation related to the contemplated Acquisition.

	
8.
	
Governing Law; Integration.  This Letter Agreement and the Definitive Agreement will be governed by the internal laws of the State of Delaware without regard to conflicts of law principles.  This Letter Agreement constitutes the entire agreement between the parties with respect to the potential Acquisition and the matters contemplated hereby, and supersedes all prior communications, agreements and understandings (written or oral) with respect to the potential Acquisition and the matters contemplated hereby.

	
9.
	
Counterparts.  It may be executed in counterparts, each of which will be an original and all of which together will constitute the same document.  .pdf or other electronic copies of signatures will be deemed to be originals.

 

 

We are ready to commence drafting and negotiation of a Definitive Agreement immediately and are extremely committed to closing the transactions on or before June 30, 2020.  Given the proposed transaction timetable, we would ask that you confirm your acceptance of the terms of the Agreement by countersigning it in the space provided below and returning a copy to the und by 5:00 p.m. Pacific time on Tuesday, March 31, 2020.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

	
Very truly yours,

	
SORRENTO THERAPEUTICS, INC.

	
 

	
/s/ Henry Ji

	
Name:
	
 
	
Henry Ji

	
Title:
	
 
	
President and Chief Executive Officer

 

ACKNOWLEDGED AND AGREED:

Nanjing Hongjing Enterprise Management Consulting Co., Ltd.

 

	
By:
	
 
	
/s/ Chunhui Men

	
 
	
 
	
Name:
	
 
	
Chunhui Men

	
 
	
 
	
Title:
	
 
	
Executive Director

 

 

 

EXHIBIT A

Summary of Terms

This Summary of Terms (“Term Sheet”) sets forth certain key terms of a possible transaction involving Sorrento and Purchaser for the purchase of Levena.

 

	
Transaction Structure:
	
 
	
The sale of Levena is expected to be structured as a purchase of all of the issued and outstanding capital stock of Levena.

	
 
	
 
	
 

	
Purchase Price:
	
 
	
$30 million, payable in cash through available cash-on-hand.

	
 
	
 
	
 

	
Definitive Agreement:
	
 
	
The consummation of the transaction will be subject to the execution and delivery by Sorrento and Purchaser of the Definitive Agreement to be negotiated between the parties.  Sorrento’s counsel shall prepare the initial draft of the Definitive Agreement.

The execution of the Definitive Agreement will require the approval of the Boards of Directors of each of Sorrento and Purchaser.

	
 
	
 
	
 

	
Certain Conditions to Closing:
	
 
	
The closing of the transaction shall be subject to the satisfaction of conditions customary for a transaction of this nature, including, among other conditions:

• receipt by the parties of any necessary governmental consents or clearances;

• accuracy of representations and warranties and compliance with covenants;

• absence of any material adverse change to the operations of Levana; and

• other conditions that, in the reasonable judgment of both parties, are appropriate for a transaction of this kind.

	
 
	
 
	
 

	
Representations and Warranties:
	
 
	
The Definitive Agreement will contain representations and warranties of the parties customary and appropriate for a transaction of this nature.

	
 
	
 
	
 

	
Covenants:
	
 
	
The Definitive Agreement will contain covenants of the parties customary and appropriate for an acquisition of this nature.

	
 
	
 
	
 

	
Indemnification of Directors and Officers:
	
 
	
The Definitive Agreement will provide that Purchaser will continue the indemnification, advancement and exculpation coverage under Levena’s arrangements existing at the signing of the Definitive Agreement and will provide customary D&O “tail coverage” to the directors and officers of Levena for a period of six years following closing of the proposed transaction.

	
 
	
 
	
 

	
Fees and Expenses:
	
 
	
Whether or not the transaction has been consummated, each party will bear its own expenses hereunder.

	
 
	
 
	
 

	
Closing of the Acquisition:
	
 
	
The Acquisition will be effected as soon as practicable after the receipt of any necessary government consents or clearances and third party consents.

	
 
	
 
	
 

	
Other:
	
 
	
Any press releases or other public announcements regarding the Acquisition, except as required by law, by either Purchaser or Sorrento or their respective advisors will be subject to the prior written approval of the other party (which shall not be unreasonably withheld, delayed or conditioned).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]